Category: McKesson Corp.
The White House has let half of the Affordable Care Act's mandatory deadlines slip by, according to a report by the non-partisan Congressional Research Service.
MASSDEVICE ON CALL — During the 1st 3 years of Affordable Care Act implementation, the Obama administration has failed to meet half of its mandatory deadlines, according to a new report from the non-partisan Congressional Research Service.
Abbott and Johnson & Johnson are among the U.S.-based companies that park billions in offshore tax havens, according to a U.S. PIRG report.
Abbott (NYSE:ABT) parked some $40 billion in 107 overseas tax havens last year, making it 1 of the top 15 U.S. companies with the most money held offshore, according to a U.S. Public Interest Research Group report issued last month.
McKesson agrees to pony up more than $2 billion for medical supplies provider PSS World Medical.
McKesson (NYSE:MCK) agreed to pay $29 per share for PSS World Medical (NSDQ:PSSI) and its medical supplies business in a deal worth $2.1 billion.
Medical device company Abiomed says the chances are slim that Medicare will grant a national coverage decision for its Impella heart pump.
Abiomed (NSDQ:ABMD) said it doesn't believe that the Centers for Medicare & Medicaid Services is likely to bestow a national coverage decision for its Impella heart pump.
Former McKesson Corp. chairman & CEO Charles McCall fails to pass muster with the U.S. Supreme Court, which rejected his bid for an appeal to reconsider his 10-year prison sentence tied to a conviction for an accounting scandal.
The Supreme Court refused to review the conviction of former McKesson (NYSE:MCK) chairman & CEO Charles McCall in an accounting scandal, meaning his 10-year prison sentence will stand.
The high court provided no comment on the denial. San Francisco, Calif.-based McKesson is the largest drug distributor in the U.S., and also deals in healthcare information technology products.
Shire plc doubles down on its $750 million buyout of Advanced Biohealing with Pervasive Therapeutics and its endothelial cell technology; also, orthopedic bellwether Biomet's Q3 results signal sector growth; McKesson beats out rivals for $32B VA deal; Insulet expands OUS distribution deal; Revolutions Medical inks Korean distribution deal; Pluromed pays back $500k Mass. loan; plus, a Funding Roundup and analysts' ups and downs.
Shire (NSDQ:SHPGY) said it agreed to acquire Pervasis Therapeutics and its endothelial cell technology for an undisclosed amount.
Fujifilm Holdings closes its nearly $1 billion buyout of SonoSite; also, Orchid closes buyout of Sandvik's medical solutions biz; Derma Sciences drops $15M on MedEfficiency; Pentax expands endoscopy ops; Accuray signs German R&D deal; GE Healthcare plans to expand in China; and analysts' ups and downs.
Fujifilm Holdings (TSE:4901) said it closed its $54-per-share acquisition of SonoSite (NSDQ: SONO).